Table 5 Diagnostic Characteristics of Functional Testing, Semi-Quantitative Coronary Artery Calcification Assessment, and Primary Prevention Guidelines in the Subgroup of Patients Referred for Functional Testing For Symptoms
Symptomatic Cohort (n = 82) | MACE | No MACE | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | PLR (95% CI) | NLR (95% CI) |
|---|---|---|---|---|---|---|---|---|
Functional Study | 40.9% (20.7%—63.7%) | 91.7% (81.6%—97.2%) | 64.3% (40.4%—82.7%) | 80.9% (74.8%—85.8%) | 4.91 (1.85 – 13.05) | 0.64 (0.45 – 0.92) | ||
Abnormal | 9 | 5 | ||||||
Normal | 13 | 55 | ||||||
Coronary Artery Calcifications (CAC) | 81.8% (59.7%—94.8%) | 66.7% (53.3%—78.3%) | 47.4% (37.4%—57.5%) | 90.9% (80.2%—96.1%) | 2.45 (1.63 – 3.69) | 0.27 (0.11 – 0.67) | ||
Present | 18 | 20 | ||||||
Absent | 4 | 40 | ||||||
Moderate or Severe CAC | 45.5% (24.4%—67.8%) | 95.0% (86.1%—99.0%) | 76.9% (50.3%—91.7%) | 82.6% (76.4%—87.5%) | 9.09 (2.75 – 30.01) | 0.57 (0.39 – 0.84) | ||
Present | 10 | 3 | ||||||
Absent | 12 | 57 | ||||||
2019 ACC/AHA Guidelinea | 36.4% (17.2%—59.3%) | 81.1% (68.0%—90.6%) | 44.4% (26.7%—63.7%) | 75.4% (68.6%—81.2%) | 1.93 (0.88 – 4.23) | 0.78 (0.56 – 1.10) | ||
Recommend statin therapy discussion | 8 | 10 | ||||||
Do not recommend statin therapy discussion | 14 | 43 |